Evaluate the Efficacy & Safety of SHR1459 Tablets in Patients With Primary

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.

This study is a phase II study to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy. ;

NCT number	NCT05136456
Study type	Interventional
Source	Reistone Biopharma Company Limited
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 15, 2021
Completion date	March 11, 2024

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05800873` - Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001	Phase 1
Recruiting	`NCT05514015` - Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy	Phase 4
Recruiting	`NCT05668403` - A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy	Phase 1
Recruiting	`NCT05696613` - A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy	Phase 3
Active, not recruiting	`NCT04629248` - A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy	Phase 3
Recruiting	`NCT05862233` - A Clinical Study of MIL62 in Primary Membranous Nephropathy	Phase 3
Not yet recruiting	`NCT06466135` - Study of WAL0921 in Patients With Glomerular Kidney Diseases	Phase 2
Not yet recruiting	`NCT06120673` - REmission in Membranous Nephropathy International Trial (REMIT)	Phase 3
Recruiting	`NCT05398653` - A Clinical Study of MIL62 in Primary Membranous Nephropathy	Phase 1/Phase 2
Recruiting	`NCT05707377` - A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy	Phase 2/Phase 3